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C-reactive •proteID
Properties and biological action with particular
reference to systemic lupus erythematosus
C. M. MACFARLANE
subsequently shown to be useful as a marker for a broad
spectrum of disease.5 It was originally thought to be absent
from normal plasma,5 but sensitive assay techniques have
shown that it is a trace constituent of normal plasma which
increases dramatically on exposure to 'inflammatory stimuli.
CRP is regarded as a nonspecific but more sensitive indicator
of inflammation tha::! the erythrocyte sedimentation rate (ESR).6
It increases from approximately 100 ng/ml in neonates to
approximately 500 - I 800 ng/ml in healthy adults,I.7 and in
the acute phase of disease it can increase 1ODD-fold in 2 days.
Human CRP is a cyclic pentamer (pentaxin) of five identical
subunits each with a single disulphide bond. It has a molecular
weight of 110 000 daltons and no detectable carbohydrate or
lipid components.2 The complete amino acid sequence is
known.s It is synthesized in hepatocytes3 and the increase in
the acute-phase response represents largely de novo synthesis
on stimulation by an extrinsic factor, interleukin I, possibly
released from macrophages. 3 Patients with liver disease, such
as alcoholic hepatitis, show only moderate « 5-fold) increases
in CRP levels. 9 In rabbits the half-life of CRP in the circulation
is 4 - 6 hours. lO
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A dramatic increase in serum C-reactive protein
levels occurs in response to specific bacterial
infection or tissue damage. This protein forms part of
the acute-phase response, and it appears to function
as an independent but relatively nonspecific part of
the immune response. It has many properties in
common with specific IgG. Absence of an adequate
C-reactive protein response may play a role in the
pathogenesis of systemic lupus erythematosus.
This short review has been based largely on the recent extensive
reviews of Gewurz er al.,l Gewurz2 and Pepys and Baltz. J
Some of the arguments may be somewhat teleological, but if
interest in an important area of intensive current clinical
research is stimulated it will have been worth while.
Summary
The acute-phase response
S At, Med J 1985; 67: 890 - 892.
The term 'acute-phase response' is generally used to describe
the increase in specific serum protein levels following infection,
tissue injury and/or inflammation. This response occurs in
most vertebrates several hours after cellular insult, and a
biological role for many of these acute-phase proteins has been
described (Table I). The acute-phase proteins would seem to
represent a circulatory scavenger system and act to limit
immune response and cellular damage during inflammation.
Under non-pathological conditions they may play a role in
normal cell regeneration. The increase in most of these proteins
is fairly modest « ID-fold), but increases of over I ODD-fold in
C-reactive protein (CRP) levels are commonly found in patients
who have experienced bacterial infections, myocardial infarction
and surgical trauma. The acute-phase response occurs after
the onset of inflammation but before synthesis of specific IgG,
and the CRP response must be seen as an important late-phase
component of the normal inflammatory response.
Structure, properties and origin of CRP
Knowledge of CRP originated with the observation by
Tillet and Francis4 in 1930 that sera from patients with febrile
disease precipitated with a C-polysaccharide (CPS) extracted
from pneumococcus. The substance responsible was a protein
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Binding properties of CRP
Binding of CRP to CPS is calcium-dependent (=2: 0,9 mM)2
and has been shown to involve anachment to monophosphate
ester groups, particularly to the phosphocholine (PC) residues
este~ed .to ~e g~a~o~e component of CPS.l The affinity
?f thiS ~lDdlDg IS. sl~Il11ar to that found in antibody-antigen
mteractlons (assOClatlon constant = 1,2 X !05M- I ).11 CRP also
binds to galactose and galactosamine residues and possesses
binding sites for calcium and polyions, e.g. histones, DNAcho~dro~tin sulphate. The binding of polyions is inhibited b;
calcIUm IOns (0,1 - 0,5 mM) and is reactivated in the presence·
of PC residues. 12
The binding of calcium, polyions or charged lipids 13•14 in-
duces structural changes in CRP, increases CRP binding to
PC. residues, and gives rise to what may be termed biologically
aCtIve CRP. CRP immobilized on a solid phase binds to
isolated low-density and very-Iow-density lipoproteins '5 and
~RP in vivo activates complement16 through the classic pathway
ID the pre~enc~ of ~omplementcomponent Cl q.n This comple-
ment activation mcreases opsonic activity and increases
clearance of CRP immune complexes through the reticulo-
endothelial system of the spleen rather than through the
liver. 18
CRP does not bind to normal healthy cells, but it is thought
~hat exposure of the phosphatidylcholine and sphingomyelin
m damaged cells and binding of activated CRP to these may
lead to complement activation, phagocytosis and splenic
clearance of the CRP complexes. 19 Deposits of CRP immune
complexes at sites of tissue injury are not as great as would be
expected, although they have been demonstrated. However,
they do not accumulate at sites of tissue damage to the same
extent as do IgG immune complexes. 1.2
Activated CRP also binds to certain bacteria and to a subset
of large g:anular Iymphocytes containing IgG-FcR receptors
(natural killer cells),' and modified CRP (but not CRP-CPS
complexes) has been shown to promote platelet activation
through an active process requiring adenosine triphosphate
and calcium.20
CRP therefore possesses many properties in common with
Ig~, ~lthough the recognition capacity is less specific. The
ubiqUitous presence of phosphatidylcholine and sphingomyelin
III cell membranes,21 and a possible increase in their accessi-
?ility, ?r in th~t of other charged phospholipids, on cell injury
IS consistent With the suggestion that CRP may have a role as a
nonspecific circulatory scavenger in diseases involving cellular
damage. 19
CRP levels in clinical practice
CRP is useful not only as a nonspecific marker for infection,
neoplasia, myocardial infarction and trauma, but it also helps
in the differential diagnosis of certain conditions,I,3,9 such as
systemic lupus erythematosus (SLE) v. rheumatoid arthritis,
bacterial v. viral infection, or ulcerative colitis v. Crohn's
disease. This has been possible because of the introduction of
simple, quantitative analytical procedures for CRP.i The levels
of CRP depend on the duration rather than the rate of
synthesis by hepatocytes, and in certain diseases, such as
rheumatoid arthritis, levels of CRP determined after serial
sampling from a single patient may be used as an indication of
the severity of the disease and response to treatment. 3, The
decrease in CRP on treatment with gold or penicillamine is
secondary to control of the primary inflammatory process.3
CRP levels have also proved useful in the diagnosis of bacterial
meningitis22 and septicaemia23 in neonates, in the detection of
postoperative infection and secondary infection in SLE24 and
in monitoring the success of renal transplants.3 CRP levels are
not increased in gastro-enteritis and ulcerative colitis, but may
be useful in the differentiation of patients with upper and
lower urinary tract infections.25,26
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CRP levels in SLE
Certain diseases associated with cellular necrosis show only
modest elevation (2 - 4-fold) of CRP levels during the acute
phase, ~.g. SLE24,27 and leukaemias.3 This may be genetically
determmed, or may be due to the inability to produce and
maintain CRP synthesis on stimulation by interleukin I, or to
a defect in interleukin production.3 CRP levels in patients with
SLE show an increase when secondary bacterial infection is
present.24 Therefore at least part of the basic synthetic and
secretory mechanisms responsible for CRP production and
part of the binding characteristics are intact. Also, animal
models (NZB/W mice) for SLE respond to injections of
casein and lipopolysaccharides with production of CRP, but
fail to show increased CRP levels with progress of the disease. 28
The reason for the modest response of CRP in the active
phase of SLE therefore remains obscure. Nevertheless, it is
felt that the lack of a marked CRP response in SLE may
contribute to its progression. 3,24 It is thought that products
released from damaged cells are normally cleared from the
circulation by interaction with CRP and other acute-phase
proteins. If this response is deficient, it would allow a specific
IgG r:esponse to be induced against partially modified cellular
products released from damaged cells, e.g. DNA, histones and
red bl<.><>d cell components. These IgG antibodies may be
serolOgically polymorphic and directed towards epitopes contain-
ing a particular arrangement of phosphate groupS.29 (This is
not dissimilar to the binding requirement of CRP, i.e. PC
phosphate ester residues.) This IgG response may sensitize the
individual to further exposure to altered cell components.
While CRP complexes are not grossly deposited at sites of
cellular damage or inflammation, possibly because of increased
splenic clearance, IgG immune complexes are, and deposits of
these in the kidney are thought to be the major cause of
morbidity in SLE.30 The absence of an adequate acute-phase
response in SLE patients may therefore contribute to the
development of this chronic, progressive disease.3,24
Studies directed at controlling CRP levels to prevent
progression of erosive disease are in progress. Initial reports31
that CRP inhibits production of T Iymphocytes have sub-
sequently been shown to be incorrect. 1,32 A deficiency of
suppressor T -Iymphocyte activity does parallel disease activity
III many SLE patients, but this may be secondary to the
disease process. 33 It has also been reported that in certain
types of SLE there is an inherited deficiency of complement
components, including Clq34 which is necessary for CRP-
mediated complement activation. 17
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coronary
Acute myocardial
•coronary arterIes
and possible
A case report
infarction with normal
viral myopericarditis
vasospasm
T. H. DIAMOND, P. LOTZOF, F. ZIADY
Case report
Summary
A young man with normal coronary arteries presented
with a transmural apical myocardial infarction. This
diagnosis was based on elevated serial cardiac
enzyme values, ECG changes, exercise scanning
with thallium-201, left ventricUlar angiography and
selective coronary arteriography. Some of the patho-
physiological mechanisms implicated in myocardial
infarction in patients with normal coronary arteries
are discussed and the probable diagnosis of a virus-
induced myopericarditis together with coronary artery
vasospasm is favoured.
S Afr Med J 1985; 67: 892 - 894.
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A 22-year-old man presented with a history suggestive of
angina. He had been well until 2 days before admission to
hospital, when he experienced a prodrome of fever, myalgia
and sweating, followed by a severe retrosternal 'pressing' chest
pain during physical training. He was a non-smoker and there
were no other risk factors for atherosclerosis.
On examination the patient was pyrexial, temperature 38°C.
Blood pressure, pulse rate, peripheral perfusion and results of
cardiac examination were normal. A full blood count showed a
leucocytosis of 12,9 x 109/1 with a predominant lymphocytosis
and atypical lymphocytes. Serial cardiac enzyme values indi-
cated myocardial necrosis with a peak creatine kinase level of
1550 lUll (normal 190 lUll) and a CK-MB fraction of 12%.
Serum urea and electrolyte values, uric acid and blood sugar
levels and a fasting lipogram were normal. Tests for auto-
immune disease were negative. Antibody titres to influenza
virus were elevated. A chest radiograph was normal.
The first ECG (Fig. 1) showed features of an acute apical
myocardial infarction, with a sinus rhythm of 70/min. The
mean QRS frontal axis was -30° and there was a left anterior
hemiblock. Loss of R wave and deep, wide Q waves were
evident in standard leads III and AVF. There was concave
